Navigation Links
IRIDEX Reports 2012 Second Quarter Results

MOUNTAIN VIEW, Calif., Aug. 2, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 30, 2012. Due to the sale of the Company's aesthetics laser business in February 2012, the Company's financial statements reflect the results of its aesthetics laser business as discontinued operations and the following commentary relates to the results of its continuing ophthalmology business. 

  • Revenues from ophthalmology were $8.4 million in the second quarter of 2012, up from $8.1 million in the prior year comparable period and up sequentially from $8.3 million in the first quarter of 2012.
  •  For the second quarter of 2012, net income from continuing operations was $0.4 million or $0.04 per diluted share, compared with net income from continuing operations of $0.9 million or $0.09 per diluted share reported in the second quarter of 2011.  Net income for both periods includes other income of approximately $0.8 million associated with the settlement payment from a 2007 patent lawsuit.
  • Gross margin for the second quarter of 2012 was 48.7%, comparable to 48.7% in the prior year period.  While the gross margins were just below our guided range, several non-recurring adjustments impacted cost of revenues in the period and indicate the Company's ability to drive gross margins to its target of 50% in the coming periods.
  • As anticipated, operating expenses edged up in the second quarter of 2012 to $4.5 million compared to $3.7 million in the prior year period. Costs in the second quarter of 2012 included major trade shows as well as increased spending on new marketing and product development initiatives.
  • Guidance for third quarter: The Company expects to achieve revenue between $8.4 million and $8.8 million, gross margins between 49% and 51% and operating expenses between $4.2 million and $4.4 million and anticipates being at breakeven for operating income.
  • President and CEO Dominik Beck said, "Demand and delivery of both capital equipment and consumable products remained stable in the second quarter with a number of promising improvements.  On the consumables side of the business, sales of our glaucoma product continued to strengthen following a focused marketing campaign that began at the beginning of 2012.  In addition, our licensing and distribution partnership is delivering strong results and current indications are for this to continue. This success is a validation of our M&A strategy as the small acquisition of RetinaLabs has already paid for itself several times over, and we anticipate similar impacts from our Ocunetics acquisition following the planned product launch in early 2014."

    Beck continued, "As we indicated last quarter, we anticipate that our increased investments in people and programs across the organization will drive overall sales growth in the second half of the year, and we intend to balance our investments in line with our revenue growth to maintain profitability for the year.

    "The most exciting marketing feedback I have received this quarter, for both clinical and investor audiences, is the accelerating adoption of MicroPulse™ for treatment of diabetic macular edema (DME). We have been working on economic models that make sense to the doctor and healthcare systems to encourage their adoption of this new treatment paradigm that has multiple benefits to the patient, and we are starting to see these models impact the purchasing decisions of our customer base. Furthermore, our experiences in DME have led us to explore opportunities for MicroPulse in the treatment of glaucoma. We are working with a number of key opinion leaders in glaucoma who have begun to explore how our minimally invasive technology can improve on the current standard of care for treating glaucoma.  If the results of these initiatives indicate an equivalent or better outcome than currently available options, we could see a significant impact to our revenues as this is a large market opportunity."

    During the second quarter 2012, the Company continued to execute its share repurchase program. Since the beginning of 2011, approximately 240,000 shares have been repurchased at an average price of $3.93. In May 2012, the Board of Directors approved an extension of the Company's share repurchase program through March 2013 and an increase in the amount of cash available for the program to a total of $4 million.

    1H 2012 Business Highlights

  • The Company launched a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
  • The Company announced the first use of MicroPulse Laser Therapy (MPLT), using the IQ 577 laser coupled with EndoProbe® instrumentation. This is the first time tissue-sparing laser therapy has been delivered through an intraocular fiber-optic probe in a surgical setting marking another important milestone towards intraocular MPLT approaches to treating a broader range of sight-threatening disease, including glaucoma.
  • The Company closed the sale of its aesthetics business to Cutera, Inc. for approximately $5.1 million. The sale allows the resources of the entire organization to now focus on the substantial and growing opportunity in the worldwide retina and glaucoma markets.
  • Conference Call IRIDEX management will conduct a conference call later today, Thursday, August 2, 2012 at 5:00 p.m. Eastern Time.  Interested parties may access the live conference call via telephone by dialing (877) 941-2333 (U.S.) or (480) 629-9724 (International) and quoting Conference ID 4555596, or by visiting the Company's website at A telephone replay will be available beginning on Thursday, August 2, 2012 through Thursday, August 9, 2012 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4555596. In addition, later today an archived version of the webcast will be available on the Company's website at

    About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at

    Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of markets in which the Company operates, the success of the Company's marketing and sales efforts,  MicroPulse laser therapy, the Company's growth strategy, the Company's acquisition strategy, sales revenue growth, operational plans and the Company's projected fiscal 2012 financial results.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2012 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


    Condensed Consolidated Statements of Operations(In thousands, except per share data)(unaudited)Three Months EndedSix Months EndedJune 30,July 2,June 30,July 2,2012201120122011Total revenues

    $8,445$8,085$16,750$16,281Cost of revenues

    4,3344,1478,6538,259Gross profit

    4,1113,9388,0978,022Operating expenses:Research and development

    1,1068902,2881,853Sales and marketing

    2,1221,7863,9863,564General and administrative

    1,2331,0222,4092,105Total operating expenses

    4,4613,6988,6837,522(Loss) income from operations

    (350)240(586)500Other (expense) income, net

    752803725807Income from continuing operations before income taxes

    4021,0431391,307Provision for  income tax

    51447223Income from continuing operations, net of tax

    3978991321,084(Loss) income from discontinued operations, net of tax

    (61)10(223)391Gain on sale of discontinued operations, net of tax

    --2,032-(Loss) income from discontinued operations, net of tax

    (61)101,809391Net income

    $336$909$1,941$1,475Net (loss) income per share:BasicContinuing operations

    $0.04$0.10$0.01$0.12Discontinued operations income

    $0.04$0.10$0.22$0.16DilutedContinuing operations

    $0.04$0.09$0.01$0.10Discontinued operations

    (0.01) income


    Weighted average shares used in computing net income per share Basic



    IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands)(unaudited)June 30,December 31,20122011AssetsCurrent Assets:Cash and cash equivalents

    ,789Accounts receivable, net

    5,9245,551Inventories, net

    7,5396,659Prepaids and other current assets

    1,228464Current assets of discontinued operations

    5586,043Total current assets

    29,03429,506Property and equipment, net

    388325Intangible assets, net


    533533Other long-term assets

    170199Restricted cash related to discontinued operations

    510Non-current assets of discontinued operations

    4841Total assets

    32,149Liabilities and Stockholders' EquityCurrent Liabilities:Accounts payable

    ,580Accrued compensation

    1,2961,180Accrued expenses

    1,0371,920Accrued warranty

    525556Deferred revenue

    8001,014Current liabilities of discontinued operations

    792,663Total current liabilities

    5,8768,913Long-Term Liabilities:Other long-term liabilities

    649810Total liabilities

    6,5259,723Stockholders' Equity:Convertible preferred stock

    55Common stock

    9392Additional paid-in capital

    42,69242,032Accumulated other comprehensive loss

    -(35)Treasury stock, at cost

    (1,374)(1,078)Accumulated deficit

    (16,649)(18,590)Total stockholders' equity

    24,76722,426Total liabilities and stockholders' equity


    SOURCE IRIDEX Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
    2. IRIDEX Reports 2012 First Quarter Results
    3. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
    4. New Medical Device Market Research Reports Tracking over $9.5 Billion of Annual Sales Volume Now Available from GII
    5. GP Strategies Reports Record Revenue of $102 Million for Second Quarter of 2012
    6. Par Pharmaceutical Companies Reports Second Quarter 2012 Results
    7. Henry Schein Reports Record Second Quarter Results
    8. Consumer Reports Investigates Vitamins And Supplements: Ten Dangers That May Surprise You
    9. STAAR Surgical Reports Second Quarter 2012 Financial Results
    10. Thoratec Reports Second Quarter Results
    11. Masimo Reports Second Quarter 2012 Financial Results
    Post Your Comments:
    (Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... ...
    (Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
    (Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
    (Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
    (Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
    (Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
    (Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
    Breaking Medicine News(10 mins):